PF-Atlas › Clinical Trials › NCT04968574
A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis
taladegib · Phase 2
Registry ID
NCT04968574
Phase
Phase 2
Status
Completed
Drug / intervention
taladegib
Sponsor
Endeavor Biomedicines, Inc.
Start
2021-08-26
About this trial
taladegib is evaluated in NCT04968574, a Phase 2 idiopathic pulmonary fibrosis study sponsored by Endeavor Biomedicines, Inc.. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT04968574 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.